Immunometabolic contributions to the pathogenesis of cardiovascular disease

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 109 - 128

Published: Jan. 1, 2025

Language: Английский

---

Omics metabolism tools in antiaging drug discovery

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 209 - 225

Published: Jan. 1, 2025

Language: Английский

---

Endogenous metabolites in metabolic diseases: pathophysiological roles and therapeutic implications

Journal of Nutrition, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

---

Macrophage polarization regulates the pathogenesis and progression of autoimmune diseases

Autoimmunity Reviews, Journal Year: 2025, Volume and Issue: 24(7), P. 103820 - 103820

Published: April 21, 2025

Language: Английский

---

Targeted drug delivery systems for atherosclerosis

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 23, 2025

Atherosclerosis is a complex cardiovascular disease driven by multiple factors, including aging, inflammation, oxidative stress, and plaque rupture. The progression of this often covert, emphasizing the need for early biomarkers effective intervention measures. In recent years, advancements in therapeutic strategies have highlighted potential targeting specific processes atherosclerosis, such as localization, macrophage activity, key enzymes. Based on this, review discusses role targeted drugs treatment atherosclerosis. It also focuses their clinical efficacy anti-atherosclerosis ability to provide more precise approaches. findings underscore that future research can concentrate exploring newer drug delivery systems further refine enhance long-term dynamic management

Language: Английский

---

Itaconate: A Potential Therapeutic Strategy for Autoimmune Disease

Scandinavian Journal of Immunology, Journal Year: 2025, Volume and Issue: 101(5)

Published: April 27, 2025

ABSTRACT Itaconate is a metabolite of the Krebs cycle, and endogenous itaconate driven by variety innate signals that inhibit production inflammatory cytokines. The key mechanism action was initially found to be competitive inhibition succinate dehydrogenase (SDH), which inhibits factors, as well its antioxidant effects. With increasing research, it discovered modifies cysteine residues related proteins through Michael addition, such modifying Kelch‐like ECH‐associated protein 1 (KEAP1) activating nuclear factor erythroid 2‐related 2 (NRF2) signalling pathway, glycolytic enzymes cellular pathway‐associated factors attenuate responses oxidative stress. It also acts on immune cells, affecting their function activity, has been increasingly shown play therapeutic role in autoimmune diseases combination these mechanisms. In conclusion, there great breakthrough research itaconate, from initial industrial application redefinition biological functions itaconate. However, with deepening we are more questions: clinical use still needs solved.

Language: Английский

---

Immunometabolism in atherosclerosis: a new understanding of an old disease

Trends in Biochemical Sciences, Journal Year: 2024, Volume and Issue: 49(9), P. 791 - 803

Published: June 27, 2024

Atherosclerosis, a chronic inflammatory condition, remains leading cause of death globally, necessitating innovative approaches to target pro-atherogenic pathways. Recent advancements in the field immunometabolism have highlighted crucial interplay between metabolic pathways and immune cell function atherogenic milieus. Macrophages T cells undergo dynamic reprogramming meet demands activation differentiation, influencing plaque progression. Furthermore, intermediates intricately regulate responses atherosclerosis development. Understanding control atherosclerosis, known as athero-immunometabolism, offers new avenues for preventive therapeutic interventions. This review elucidates emerging intricate metabolism immunity underscoring significance enzymes metabolites key regulators disease pathogenesis targets.

Language: Английский

---

The anti-inflammatory effects of itaconate and its derivatives in neurological disorders

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 78, P. 37 - 49

Published: July 6, 2024

Almost 16 % of the global population is affected by neurological disorders, including neurodegenerative and cerebral neuroimmune diseases, triggered acute or chronic inflammation. Neuroinflammation recognized as a common pathogenic mechanism in wide array conditions Alzheimer's disease, Parkinson's postoperative cognitive dysfunction, stroke, traumatic brain injury, multiple sclerosis. Inflammatory process central nervous system (CNS) can lead to neuronal damage apoptosis, consequently exacerbating these diseases. Itaconate, an immunomodulatory metabolite from tricarboxylic acid cycle, suppresses neuroinflammation modulates CNS immune response. Emerging human studies suggest that itaconate levels plasma cerebrospinal fluid may serve biomarkers associated with inflammatory responses disorders. Preclinical have shown its highly cell-permeable derivatives are promising candidates for preventing treating neuroinflammation-related The underlying involve regulation cells signaling pathways molecules Nrf2/KEAP1 pathway, reactive oxygen species, NLRP3 inflammasome. Here, we introduce metabolism function synthesis development derivatives. We summarize potential impact therapeutic on molecules, based preclinical evidence via various disorder models. also discuss challenges solutions clinical translation promote further research

Language: Английский

---

Nanoparticle-based itaconate treatment recapitulates low-cholesterol/low-fat diet-induced atherosclerotic plaque resolution

Cell Reports, Journal Year: 2024, Volume and Issue: 43(11), P. 114911 - 114911

Published: Oct. 29, 2024

Language: Английский

---

Targeting Unc5b in macrophages drives atherosclerosis regression and pro-resolving immune cell function

Proceedings of the National Academy of Sciences, Journal Year: 2024, Volume and Issue: 121(44)

Published: Oct. 22, 2024

Atherosclerosis results from lipid-driven inflammation of the arterial wall that fails to resolve. Imbalances in macrophage accumulation and function, including diminished migratory capacity defective efferocytosis, fuel maladaptive plaque progression. The neuroimmune guidance cue netrin-1 has dichotomous roles partly due its multiple receptors; atherosclerosis, promotes survival retention via receptor Unc5b. To minimize pleiotropic effects targeting netrin-1, we tested therapeutic potential deleting Unc5b mice with advanced atherosclerosis. We generated fl/fl Cx3cr1 creERT2/WT mice, which allowed conditional deletion Un5b (∆ MØ ) monocytes macrophages by tamoxifen injection. After inducing atherosclerosis hepatic PCSK9 overexpression western diet feeding for 20 wk, was deleted hypercholesterolemia normalized simulate clinical lipid management. Deletion myeloid led a 40% decrease atherosclerotic burden reduced complexity compared WT/WT littermate controls (Ctrl ). Consistently, content 50% ∆ Ly6C hi monocyte recruitment retention. Compared Ctrl plaques had necrotic area fewer apoptotic cells, correlated improved efferocytotic -deficient vivo vitro. Beneficial changes dynamics upon were accompanied an increase atheroprotective T cell populations, T-regulatory Th2 cells. Our data identify as target induce pro-resolving restructuring immune cells promote regression.

Language: Английский

---